Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Trial to Determine the Safety and Immunogenicity of Typhax Delivered IM
NCT03926455 is registered in ClinicalTrials.gov with Matrivax Research and Development Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Trial to Determine the Safety and Immunogenicity of Typhax Delivered IM
- Lead sponsor
- Matrivax Research and Development Corporation
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- March 28, 2016
- Completion date
- February 15, 2017
- Enrollment
- 45 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.